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This document of the European Society of Human Genetics contains recommendations regarding responsible implementation of
expanded carrier screening. Carrier screening is deﬁned here as the detection of carrier status of recessive diseases in couples or
persons who do not have an a priori increased risk of being a carrier based on their or their partners’ personal or family history.
Expanded carrier screening offers carrier screening for multiple autosomal and X-linked recessive disorders, facilitated by new
genetic testing technologies, and allows testing of individuals regardless of ancestry or geographic origin. Carrier screening aims
to identify couples who have an increased risk of having an affected child in order to facilitate informed reproductive decision
making. In previous decades, carrier screening was typically performed for one or few relatively common recessive disorders
associated with signiﬁcant morbidity, reduced life-expectancy and often because of a considerable higher carrier frequency in a
speciﬁc population for certain diseases. New genetic testing technologies enable the expansion of screening to multiple
conditions, genes or sequence variants. Expanded carrier screening panels that have been introduced to date have been
advertised and offered to health care professionals and the public on a commercial basis. This document discusses the
challenges that expanded carrier screening might pose in the context of the lessons learnt from decades of population-based
carrier screening and in the context of existing screening criteria. It aims to contribute to the public and professional discussion
and to arrive at better clinical and laboratory practice guidelines.
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It is estimated that there are more than 1300 recessively inherited
disorders (autosomal and X-linked), whose symptoms range from the
very mild to severe, cumulatively affecting at least 30 in every 10 000
children.1,2 This means that approximately 1–2 in 100 couples are
couples who are at risk of having a child affected with a recessive
genetic condition.3 Currently, the standard practice is to offer carrier
testing to individuals at adult age who have a family history of a
particular recessive disease; to the partners and relatives of identiﬁed
carriers, or to the partners of people with the disease. However, in this
way, only a minority of carrier couples will be identiﬁed, since the
majority of affected children are born to couples with no previous
known family history, and only a minority of relatives in high-risk
families request carrier testing.4 The document was prepared by
members of the Public and Professional Policy Committee (PPPC)
of the European Society of Human Genetics (ESHG) and approved by
the ESHG Board on 6 September 2015. This document is also
endorsed by the British Society for Genetic Medicine (BSGM) Board.
A summary of this document with the recommendations will be
published in print in the European Journal of Human Genetics.5 The
below full version with extensive references is published online only.
Basic concepts of carrier screening
Carrier screening is deﬁned here as a type of medical investigation to
detect whether or not carrier status for a recessive disorder is present
in a couple or a person, who does not have an a priori increased risk of
being a carrier based on their or their partners’ personal or family
disease history. Carrier screening offered before or during pregnancy
determines a couple’s risk of having a child with a recessive inherited
disorder, thereby facilitating reproductive choices for those at a high
risk of having a child with a serious genetic disorder. Identifying
carriers of either autosomal recessive or X-linked disorders has the
potential to beneﬁt prospective parents. When both partners are
identiﬁed carriers of the same autosomal recessive disease, they have a
one in four risk in each pregnancy of having a child affected by this
disease. For X-linked disorders, half of the male offspring of a carrier
mother will typically be affected. In this document we deﬁne ‘carrier
couples’ as couples at risk of having offspring with an autosomal
recessive or X-linked disorder.
Carrier screening can be considered at different life stages, for
example, by individuals or couples before pregnancy (preconception
carrier screening) or even before relationships commence (premarital,
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or pre-relationship carrier screening, for example, high-school
screening), and by women during pregnancy and their partners
(prenatal carrier screening). There are advantages and disadvan-
tages to screening at each particular stage. For example, although
prenatal screening is considered the most practical since pregnant
women generally come to medical attention, the preconception
period might be considered better timing with regard to the
primary aim of screening because it results in more reproductive
options being available besides prenatal diagnosis – thus in
maximizing meaningful choices–6 including preimplantation
genetic diagnosis (embryo selection), use of non-carrier donor
sperm and/or oocytes, refraining from pregnancy or adoption.
Furthermore, in some cultures, where the focus of screening is on
spouse/partner selection or carrier matching, changing the choice
of partner to prevent disease is an option.
Carrier screening should be distinguished from newborn screening,
which aims to detect newborns with serious treatable disorders for
early treatment and prevention, and their roles are considered
complementary.7 For some disorders, newborn screening automati-
cally yields carrier status information as an unsolicited ﬁnding, because
of the nature of the test being employed. Since carrier status has no
immediate implications for the child, disclosure of this information to
parents has raised much debate.8
Carrier screening can be offered on an occasional basis, organised as
a population-based offer as part of a screening programme irrespective
of risk status, or aimed at speciﬁc high-risk populations based on
ancestral background. Carrier screening can be offered to individuals
or couples. For couples, screening tests can be performed simulta-
neously or sequentially (after the ﬁrst partner tests positive). More-
over, test-results can be communicated to partners individually (ie,
disclosure of individual test-results) or couple-based (ie, positive
results are communicated only to those couples in which both
partners are found to be carriers).
Although in most Western countries there is consensus that the aim
of reproductive screening, including carrier screening, should be to
enhance reproductive autonomy and enable meaningful reproductive
choices, from a global perspective there are different views. In some
communities with a high burden of severe disease, population-level
prevention is regarded as the appropriate aim of carrier screening, and
in those cases reduced birth rates of affected children may be regarded
as the measure of success.9 Furthermore, although not to date
considered a primary aim, carrier screening might also contribute to
early therapeutic procedures in the neonatal (and potentially also
prenatal) period for certain conditions; closer monitoring and
surveillance – and hence earlier diagnosis – of infants born to known
carrier couples which consequently might reduce morbidity and
mortality related to these disorders.
From single diseases to expanded screening panels
So far, carrier screening has been performed for relatively common,
recessive disorders associated with signiﬁcant morbidity and reduced
life-expectancy. Examples are carrier screening for cystic ﬁbrosis (CF)
(offered in countries including the United States, Australia and Italy)
and beta-thalassaemia (offered in, eg, Cyprus, Sardinia, Israel and
Turkey). Other examples include panels of speciﬁc disorders targeted
at speciﬁc communities, such as people with Ashkenazi Jewish (AJ)
ancestry, which has resulted in a substantial lowering of the number of
children born as affected with diseases such as Tay-Sachs disease.10
Disadvantages of ancestry-based screening are that diseases are
not limited to speciﬁc groups and it is difﬁcult to deﬁne who is at
risk because of multi-ethnic backgrounds.11 In contrast to a
diagnostic setting, where signs/symptoms lead to suspicion of a
particular condition, carrier screening usually involves panels of
sequence variants that are the most frequent and known to affect
function.
With the introduction of new (faster and cheaper) genetic
technologies, it is now possible to detect a much larger set of sequence
variants, but also to simultaneously screen for many different diseases
at a faster turnaround time without signiﬁcantly increasing costs.
Moreover, while some current screening programmes are ancestry-
based, expanded carrier screening (sometimes referred to as ‘pan-
ethnic’ or ‘universal’) allows testing of all individuals regardless of
ancestry, which in this respect increases equity and potentially reduces
the risk of stigmatisation of ethnic groups. An increasing number of
commercial laboratories, both in North America, Australia and in
Europe, already offer panels for carrier screening for over 100 diseases.
However, were these panels to be implemented in routine health care,
this could pose major challenges for health care professionals.
Responsible implementation of expanded genetic carrier screening
raises many technical, ethical, legal and social questions, including
among others: Which diseases and sequence variants should be
included in the panels and on what basis will these decisions be
made? What are public and professional attitudes and preferences
towards expanded carrier screening panels? How can pre- and post-
test education and counselling be optimised to facilitate informed
decision making?
Challenging the principles of carrier screening
A distinguishing feature of screening compared with diagnostic testing
is that a test is usually offered to people without any sign or symptoms
of a speciﬁc health problem and without a priori increased risk. To
justify screening, a screening programme has to meet certain criteria,
and in many countries the Wilson and Jungner criteria remain the
used standard, albeit with some modiﬁcation for developments in
genetics.12 For reproductive screening – as stated above – the aim is
generally not for early diagnosis/prevention and treatment, but to
facilitate reproductive decision making.13,14 An important screening
criterion is that the natural course of the disease screened for should
be adequately understood, and that an acceptable and reliable test
should be available with known sensitivity, speciﬁcity and predictive
values. In reproductive screening where couples may be faced with the
choice of avoiding or terminating a pregnancy, their autonomous
decision making should be facilitated. In 2003, the ESHG issued a
document on the principles, techniques, practices and policies that
impact population genetic screening programmes in Europe. This
opined that ‘genetic screening goals and the target population must
be well deﬁned; laboratory quality control stringent, with limits of
results clearly delineated; the conﬁdentiality of the information
protected by authorities; procedures to protect individual and
family privacy established in advance; voluntary participation;
genetic counselling offered and educational programmes in place;
and long-term outcomes monitored and evaluated’.15 Expanded
carrier screening panels pose a challenge to these criteria and
principles, and any implementation will need a justiﬁcation in
terms of proportionality in which the advantages outweigh the
disadvantages. However, when the topic was discussed by the UK’s
Human Genetics Commission, there was a deﬁnite view that, while
such an extended range of carrier screening did present certain
challenges to health services, there was no reason for such
screening not to be pursued.16
In 2013, the American College of Medical Genetics (ACMG)
published a position statement outlining the important issues related
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to prenatal/preconception expanded carrier screening.17 The more
extensive joint statement of the ACMG, American College of
Obstetrics and Gynecologists (ACOG), National Society of Genetic
Counselors, Perinatal Quality Foundation, and Society for
Maternal-Fetal Medicine in 201511 suggests, among others, the
components of consent for expanded carrier screening, informa-
tion related to post-counselling, criteria for conditions to be
included on expanded carrier panels, recommendations related
to interpretation of molecular ﬁndings, as well as needs for further
data collection and research.
This paper: (a) reﬂects on these new challenges in the context of
lessons learnt from several decades of population-based carrier
screening, (b) contributes to the public and professional discussion
on expanded carrier screening, (c) contributes to the development of
clinical and laboratory guidelines, and (d) provides recommendations
for health care policy and professionals. The paper was prepared by
members of the PPPC of the ESHG and recommendations were
posted on the ESHG website from 4 February 2015 to 15 March 2015,
for membership consultation and comments from external experts.
The ﬁnal version was approved by the ESHG Board on 6 September
2015, and also endorsed by the BSGM Board. This document starts
with an outline of attitudes of health care professionals and the public
towards carrier screening, followed by an overview of carrier tests
currently available and discussed against the Analytic validity, Clinical
validity, Clinical utility, Ethical, legal and social implications (ACCE)
Framework, and ends with (consensus) recommendations.
Summary points (I)
 The primary goal of carrier screening is to facilitate informed reproductive
decision making by identifying those couples at risk of having an affected child
with an (autosomal or X-linked) recessive disorder.
 Expanded carrier screening offers carrier screening for multiple recessive
disorders, facilitated by new genetic testing technologies that enable the
expansion of screening without signiﬁcantly higher costs. An increasing number of
commercial laboratories already offer expanded carrier screening.
 Expanded carrier screening allows testing of all individuals regardless of ancestry
or geographic origin (‘pan-ethnic’ or ‘universal’), which in this respect increases
equity and reduces the chance of stigmatization. Responsible implementation of
expanded genetic carrier screening, however, raises many technical, ethical, legal
and social questions.
 The best time to offer screening is during the preconception period, since
identifying carrier couples before pregnancy allows the greatest number of options
with more time to make an informed decision. Efforts should be made to facilitate
this timing.
ATTITUDES OF HEALTH CARE PROFESSIONALS AND THE
PUBLIC
The attitudes and perceived barriers, and concerns among health care
professionals and the general public towards carrier screening for
speciﬁc genetic disorders have been well researched. However, it is
difﬁcult to know how or whether these ﬁndings extrapolate to
expanded carrier screening: Some ﬁndings may be removed or
reduced, while new issues may arise, as we will discuss.
Health care professionals’ attitudes and perceptions
The positive attitude of potential providers is vital to the success of a
screening programme. The attitudes and perceptions of health care
providers towards carrier screening have been studied primarily for
individual genetic disorders, especially for CF and haemoglobinopa-
thies (HBPs; sickle cell disease and thalassaemia). Generally there is a
positive attitude towards carrier screening,18 however, several concerns
and barriers exist including the psychological impact of screening, lack
of knowledge, lack of guidance and costs. Sufﬁcient pre- and post-test
education and counselling have an important role in limiting the
possible negative psychological effects of carrier screening, since
improved genetic knowledge is inversely correlated with the testee’s
anxiety.19 A lack of knowledge/adequate education among both
professionals and the lay public has been a major concern among
health care professionals in many surveys.20–23 In addition, lack of
time to offer screening and counselling has been mentioned as an
important barrier.22,24,25 Additional barriers are prohibitive costs
(or lack of reimbursement), lack of supporting services,21,22,26 and
lack of awareness of (or use of) existing guidelines.20,21,27
That said, many countries have no clear guidelines or policies
for carrier screening, and testing is only offered at a local level, or
as pilot projects, resulting in very few health care professionals
providing screening to their patients. For example, in the Nether-
lands, the lack of a national policy was seen as a major barrier to
offering carrier screening for HBPs.28 Even in countries where
guidelines do exist, for example, in the United Kingdom, service
delivery was initially poor or patchy.29 In the United States several
ACMG/ACOG recommendations on carrier screening for different
disorders exist and are frequently updated. For example, the
ACOG launched CF carrier screening guidance in 2001. However,
a decade later a concerning percentage of obstetricians are still
ignorant about their existence.20
In 2012, experiences and opinions on expanded carrier screening
for 4100 diseases of variable severity were assessed among 222
gynaecologists and obstetricians in the United States. Although there
may have been a bias towards those who are the most informed about
the topic, 15% of the professionals offered expanded carrier screening
to all patients, while 52.1% offered it upon a patient’s request.30 The
majority of respondents (65.8%) in this study believed that the
optimal time for expanded carrier screening was prior to conception.
However, preconception carrier screening is considered less feasible by
health care professionals,18,31 and evidence from carrier screening
practice shows that it is mainly offered in pregnancy.20,21,31 In a focus
group study by Cho et al.32 40 genetics professionals stressed the
importance of pre- and post-test counselling and opined that
counselling should be provided by a clinician with expertise in
communicating genetic information. Ready et al.33 surveyed the
attitudes regarding expanded genetic carrier screening among 203
health care providers, of whom 61% were physicians. This study
indicated that the majority of participants believed that a post-test
consultation with a genetic counsellor would be helpful (84%), or
indeed essential (78%). Most people undergoing carrier screening will
not be familiar with the conditions it can detect, so that many
questions are likely to arise for carrier individuals/couples, and may
require referral to other health care professionals who can answer
these. Screening for multiple diseases could thereby act as drivers to
refer patients with abnormal screening results to a genetic service,
resulting in signiﬁcant service pressures. New service models could be
developed with genetic counsellors working more closely with primary
care providers and telemedicine genetic counselling (ie, medical
information exchange via electronic communication, for example
using a real time video link). Cho et al.32 also highlighted concerns
that expanded carrier screening could not fully rule out the possibility
of severe recessive diseases since rare sequence variants would not be
detected, thus resulting in ‘false reassurance’ about reproductive risks
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with negative results. Some participants felt that selective panels would
be more appropriate for some people belonging to high-risk groups.
Potential providers of expanded carrier screening cite the (likely)
lower costs as a major advantage over conventional (single gene
sequence variants) screening and despite their concerns about the
technical limitations of expanded carrier screening, genetic profes-
sionals considered the possibility of widening the range of sequence
variants without signiﬁcant increases in the cost to be an advantage.32
It is important to note, however, that the true costs of expanded
carrier screening includes follow-up counselling needs and investiga-
tions and these are not included in marketing claims of lower costs.34
Future research could usefully investigate the additional costs, and the
competences and education required for expanded carrier screening.
The capacity of the health care system (and in particular of the
genetics professionals) to deal with information and counselling, as
well as downstream services demands, should be properly evaluated up
front before decisions regarding implementation are taken.
Public attitudes
The identiﬁcation of the gene causing CF in 1989 was followed by
extensive research on public attitudes with regard to carrier screening
for this disorder. A recent systematic review summarising 23 years of
research shows strong support among the public: The majority of
people (range 60–100%) believe CF carrier screening should be
available, while 80–96% believe that it should be routinely offered.35
Most – like health care professionals – thought the best time to offer it
would be prior to conception.35,36 The highest interest in carrier
screening was observed among people of reproductive age, in
particular if they had no children at the time of the survey.37 Previous
studies have shown that the majority of parents of a CF child and adult
patients also support population carrier screening38–40 and only a
minority of parents and patients feel that testing should be restricted
to families with a family history of the disease.38 Some fear, however,
that the expansion of screening to more diseases may lead to greater
feelings of guilt and blame surrounding a potentially avoidable
disorder.41
In some genetically isolated communities, carrier screening is a
well-known and well-accepted practice.42–45 Positive attitudes in
the AJ population have been reported, not only towards carrier
screening in adults (eg, in the context of a premarital conﬁdential
carrier matching programme for ultra-orthodox – Dor Yeshorim
programme–46 or offered more openly),47 but also towards screening
adolescents in high schools.48,49 Starting in the 1970s with the offer of
screening for Tay-Sachs Disease (TSD), carrier screening in this
community has already expanded to include many more
diseases.50,51 Due to founder effect, the AJ population is at increased
risk for several speciﬁc recessively inherited diseases, sometimes
referred to as ‘Ashkenazi Jewish Diseases’.50 The attention that it has
been given may have led to a higher sense of vulnerability in this
population and thus more interest in testing for multiple diseases
compared with the general population.50,52 Members of this commu-
nity generally accept a screening offer, even for diseases with lower
carrier frequencies and/or detectability,51 and also if the disease in
question is relatively mild.50 In particular, this last issue has already
created lively discussions.53,54 The expansion of carrier screening to
other diseases may, in part, be driven by the demand of the AJ
population.51 A survey study among 145 individuals of the Dutch
Jewish community showed that 56.6% agreed that a carrier screening
offer should include all diseases couples want to be tested for.55 In this
study, no convincing preference for ancestry-based or pan-ethnic
carrier screening was shown. The most important reason to prefer an
ancestry-based panel was to prevent high health care costs. As costs of
expanded carrier screening panels are most likely to drop in the future,
it is expected that these expanded panels will receive more support in
the future.
In some countries where a severe recessive disorder is common, the
severity of the disease has led to successful screening strategies, in
terms of high uptake and awareness. For example, beta-thalassaemia
carrier screening has a long and successful history in several at-risk
populations in the Mediterranean area.56 In some European countries,
disorders that were previously uncommon have now become much
more frequent due to global migration. For example, the prevalence of
HBPs (sickle cell disease and thalassaemia) has risen in Northern
Europe due to the increased number of immigrants from Africa and
Mediterranean regions. Studies have shown that migrant populations
in countries such as the United Kingdom and the Netherlands have
positive attitudes towards screening for these disorders, although
acceptance of reproductive options, such as prenatal testing and
termination of affected pregnancies, may be low among particular
groups.29,57–62
A limited number of studies have addressed attitudes towards
screening for other conditions, such as spinal muscular atrophy63 and
Fragile X syndrome,64–66 and despite the heterogeneous phenotype
and complicated inheritance of the latter, similar positive attitudes
have been found. More research is needed to assess general public
perceptions about the beneﬁts and barriers to expanded carrier
screening panels.
Uptake
In countries where carrier screening programmes aim to enhance
reproductive decision making for couples at risk for a disease, helping
and empowering couples to make an informed choice is considered a
prerequisite for a successful programme. Here uptake per se is
considered of less importance, while the harder-to-measure
autonomous decision making that testing facilitates is the key
concept. The effectiveness of a screening programme should ideally
be assessed in terms of a measure of informed choice.67 This
implies that the decision to accept or decline screening must be
based on relevant knowledge, free of coercion from others and
consistent with the decision-maker’s values. Insight into the factors
that inﬂuence uptake, and the reasons why individuals or couples
decide to have a test or not might indicate the degree of informed
choice.
Population-based carrier screening for CF has mainly been offered
during pregnancy, in particular to women attending a routine
antenatal clinic visit, where uptake rates of 46–99% have been
reported.35 In contrast, despite the overall positive attitudes of the
general public, the uptake rate of any form of preconception screening
is much lower, even when screening is offered free of charge.62,68,69
Whether these ﬁndings reﬂect a greater interest in screening among
pregnant women or simply represent an easier point at which to offer
screening (eg, because blood samples have often already been taken at
time of offer, and tests in pregnancy are generally regarded as
important) is not clear. The method of invitation is also important
for CF carrier screening uptake: measured to be ~ 10% when
invitations were sent by letter, yet 25–87% with active opportunistic
testing, that is, a personal approach and immediate possibility for
testing.31,70 This could reﬂect supply push rather than population
demand but there is inevitably also a relationship between the two.71
When carrier screening is offered alongside other tests, informed
decisions may in fact be compromised. A reﬂection period to decide
whether or not to have the test would give people the opportunity to
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make a decision based on the perceived beneﬁts and not just because it
is offered.70 In contrast, the low uptake rate achieved by mailed
invitations might be due to other reasons such as lack of knowledge
and perceived barriers (eg, inconvenience of the time or location for
having the test).37,68,69 Other factors also inﬂuence the uptake of
screening, again most extensively studied for CF.35,37 Besides
factors related to individual characteristics (eg, education) and
perceptions (eg, of the beneﬁts and barriers of screening) factors
related to the quality of delivery of genetic services, carrier testing
information and counselling also inﬂuence the screening uptake.
For example, the low uptake of HBPs carrier testing among
immigrants in the United Kingdom was partly due to a lack of
knowledge among physicians about the diseases, misconceptions
about the immigrants’ norms and values,72 and offering a test late
in pregnancy.73 Evidence about the types of interventions that
could improve informed decision making about screening is
limited and further research into these deserves priority, especially
in disadvantaged groups.74
Would expanded screening inﬂuence uptake? It is likely that
individuals and couples who would not consider any of the repro-
ductive options arising as a result of carrier screening (eg, termination
of pregnancy, using donor gametes or choosing another partner), will
neither be interested in having expanded screening. For some, offering
screening for more than one disease may increase the perceived
beneﬁts of testing (greater chance of ﬁnding that they are a carrier
couple) and such couples may be more willing to participate.
Expanding carrier screening in AJ high schools from one disease
(TSD) to seven diseases resulted in an increase in uptake.19 The
authors, however, concluded that another variable – the use of cheek
brush swabs instead of taking blood samples for DNA extraction –
may also explain this increase.19 The need for blood tests is cited as a
barrier by people who declined screening, especially in high school
screening programmes.37 More research is needed on how uptake is
affected by the expansion of panels and whether individuals and
couples can make informed decisions with respect to such an offer.
REPRODUCTIVE DECISION MAKING
With regard to CF carrier screening, a recent review has demonstrated
that 80–100% of the carrier couples identiﬁed through primarily
prenatal screening, decided to have prenatal diagnosis to ﬁnd out if
their unborn child had CF.35 Once conﬁrmed, termination of
pregnancy was undertaken for almost all of the affected fetuses. Less
is known about prospective carrier couples identiﬁed preconception-
ally as much longer follow-up is needed to assess their subsequent
reproductive decisions. While improving informed reproductive
choice is considered as the primary goal of screening, this may also
have as a consequence, although it is not the primary aim, that the
birth prevalence will be reduced. Expanded carrier screening may
result in more couples deciding to have prenatal diagnosis or
preimplantation genetic diagnosis, abstain from children or use donor
gametes, and thus as a consequence, may lead to a reduction in the
number of children born with the diseases that are screened for.
In communities with high frequency of carrier status and a high
disease burden, and where carrier screening is common, uptake rates
are also very high. A resultant decline in births of children with the
disease in question has been observed. For example, a 90% reduction
of children born with TSD was observed in the AJ community as a
result of carrier screening, followed by prenatal diagnosis when
indicated.10 But in this community, the reduction of the burden of
disease or prevention is also regarded as an explicit aim of screening
and well-accepted by the community.9 In Cyprus, both in the republic
of Cyprus and Northern Cyprus, carrier screening for beta-thalassae-
mia, initially a mandatory programme to actively discourage marriage
between carriers of thalassaemia, has resulted in a decrease of the birth
prevalence by more than 95%.27 Similar results were found in
Sardinia56 and Turkey.75 In Turkey, the Haemoglobinopathy Control
Programme was initiated issuing a law in 1993 and starting (especially
premarital) screening in high-risk provinces.76 Since 2003, it has been
offered more widely, accompanied by an extensive public eduational
programme.75 In other countries, such as Iran, Bahrain and Saudi
Arabia, (mandatory) premarital screening programmes have become
widely accepted;27 some of these programmes clearly mention
prevention as their aim.77 However, these programmes have not
necessarily led to a reduction of affected births in the related countries
as a consequence of several factors, including couples who marry
despite being diagnosed as carrier couples and prenatal diagnosis not
being available or offered.77–79
Summary points (II)
 Research among health care providers has identiﬁed the following challenges to
the implementation of carrier screening programmes: low genetic literacy among
patients and medical practitioners, costs and reimbursement issues, variability
among different national health services and regional health systems as well as
lack of or limited use of professional guidelines.
 Attitudes towards the offering of carrier screening among the general public were
found to be overwhelmingly positive. The actual uptake of carrier screening,
however, varies greatly among countries and communities. The uptake is highest
in some Middle Eastern and Mediterranean regions, where screening (for beta-
thalassemia) is mandatory. In addition, some ethnic groups, such as Ashkenazi
Jewish communities, have traditionally been highly receptive to carrier screening
for recessive conditions.
 Carrier screening programmes aiming to enhance reproductive decision making
for couples should include in its evaluation a measure of informed choice.
THE CARRIER SCREENING TEST
Although rapidly evolving genomic technologies facilitate carrier
screening for a growing number of diseases simultaneously, developing
a screening panel which meets the criteria that justify screening,
including known positive and negative predictive values for each test,
remains a challenge. One of the frameworks to assess new emerging
tests is the ACCE framework developed by the Centers for Disease
Control and Prevention (CDC, Atlanta, GA, USA), National Ofﬁce of
Public Health and the Foundation of Blood Research (http://www.cdc.
gov/genomics/gtesting/ACCE/; last accessed 18 August 2015).
Analytic validity
Analytic validity of a genetic test deﬁnes its ability to accurately and
reliably measure the genotype of interest. Current commercial
providers use mostly microarray-based genetic tests covering most
frequent sequence variants in selected genes. Although the results may
differ between providers, it has been shown that the validity of
microarray test results is comparable to blood-based single-gene
carrier tests.80 Alternatively, whole genes, and not only selected
sequence variants, can be enriched and sequenced by next-
generation sequencing (NGS).81 Analytical validity of targeted
NGS is comparable to Sanger sequencing,82 while concordance
and sensitivity of whole-exome and whole-genome sequencing was
reported to exceed 97 and 95% compared with high-density
microarrays; main sources of non-uniformity included variance
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in depth of coverage, artefactual variants resulting from repetitive
regions and larger structural variants.83 Clinical use of NGS is
still in its early phase and recommendations are being developed
for assuring the quality of NGS in clinical laboratories;84,85 never-
theless, it is expected that companies start moving to NGS for their
expanded panels. For certain conditions, such as HBPs and Tay-
Sachs disease, biochemical methods may provide better accuracy
than molecular methods.11
Clinical validity
Clinical validity of a genetic test deﬁnes its ability to detect or predict
the associated disorder, or in our case carrier status. It is described in
terms of sensitivity, speciﬁcity, positive and negative predictive values
and is inﬂuenced by the prevalence of the tested disorder or carrier
state, penetrance and genetic or environmental modiﬁers. Most
genetic disorders are characterised by allelic heterogeneity, which
means that more than one sequence variant in a given gene is
associated with the phenotype. For example, more than 2000 sequence
variants have been reported in the CFTR gene associated with CF
(http://www.genet.sickkids.on.ca/StatisticsPage.html; last accessed 18
August 2015). The most common sequence variant p.Phe508del in CF
patients demonstrates a signiﬁcant population speciﬁc distribution
with decreasing prevalence from Northwest to Southeast Europe, and
fewer than 20 sequence variants occur at a worldwide frequency of
more than 0.1%. On average, commercial providers of carrier testing
only test a small number of all known sequence variants in a particular
gene, while the average number of sequence variants associated with
genes included in the panel according to the Human Genetic Mutation
Database (HGMD) is 284 per gene (http://www.hgmd.cf.ac.uk/ac/
index.php; last accessed 11 August 2014).86 Furthermore, several
sequence variants are very rare or associated with a milder or variable
phenotype, however, data on the exact molecular pathology (frequency
of variants in a certain gene or proportion of variants in different
genes if genetic heterogeneity is present) for a given genetic disorder in
different populations are still often not available. As the carrier
screening panels are ﬁxed in the microarray based testing and focused
to a limited number of sequence variants, they cannot comprehen-
sively address the molecular pathology in diverse populations
(‘pan-ethnic’ setting), neither the spectrum of tested genes nor the
spectrum of sequence variants.
All these factors, (population speciﬁc molecular pathology and
number of sequence variants and genes tested per genetic disorder)
affect the clinical sensitivity (proportion of the carriers identiﬁed if a
tested person is a carrier) of the test as well as the negative clinical
predictive value (probability that the tested person is not a carrier if
the test is negative) and varies depending on variant frequency in a
particular population. NGS approaches have the potential to increase
clinical sensitivity81,87 since several thousands of variants are tested in
one diagnostic assay. NGS testing may be bioinformatically limited to
the variants, known to affect function or designed to detect new
sequence variants as well. In the latter case, a NGS approach will at
times also generate variants of as yet unknown signiﬁcance as well as
potential incidental or unexpected ﬁndings. NGS approaches may be
based on target enrichment methodology including coverage of the
exonic, intronic and regulatory regions. Alternatively, if exome
sequencing is used as the NGS approach, sequence variants in several
intronic and regulatory regions might remain undetected. Further-
more, certain exonic regions do not yield enough sequencing data to
make high-quality genotype detection possible. The positive predictive
value, the chance of developing the disease if the test is positive, will be
different for different disorders as a function of the penetrance and
expressivity of different sequence variants. This also means that a given
variant may be associated with different clinical severity or disease
manifestation even in the same family. For prospective carrier couples,
the prediction of the phenotype in an affected child will be even more
difﬁcult based on the combination of the variants of both parents. The
exact prevalence rate for recessive disorders worldwide is not
known and is complicated by geographic or population variability.
A systematic survey of epidemiological data in Europe is offered by
Orphanet,88 but information is not population speciﬁc. Bell et al.81
have shown that the average carrier burden of severe childhood-onset
recessive disorders after screening for 448 genes in 104 unrelated
samples was 2.8 (range 0–7). A screening panel of 108 disorders and
417 disease causing variants identiﬁed 24% of individuals as carriers
for at least one variant.89 On the other hand, the Genome of the
Netherlands Project demonstrated a high frequency of some of the
HGMD variants that affect function associated with autosomal
recessive disorders in the healthy Dutch population.90 In fact, many
tested individuals carrying two copies of the allelic variant should have
been affected by diseases which implies a considerable number of false
positive disease-causing variants in the HGMD81,91 (or potentially
other mutation databases), incomplete penetrance/variable expressivity
of variants, or both. Consequently, clinical validity of carrier screening
might be uncertain for several variants, presently considered as
disease-causing.
Clinical utility
The clinical utility of a genetic test refers to the value of the genetic
information to medical practice and whether the test can signiﬁcantly
improve patient outcomes. For preconception carrier screening,
clinical utility is the increase in a couple’s reproductive autonomy
and choice. In the future, preconception carrier screening might
facilitate better perinatal diagnosis with early management of genetic
disorders. Current commercial providers often market their genetic
tests by highlighting the possibility of treatment either in pregnancy or
after birth, even though hard evidence for this is lacking or clinical
relevance is not clear from the selection of diseases in the screening
panel. For example, haemochromatosis is often included in the
panel,92 despite the lack of evidence of beneﬁt in general population
screening, let alone in reproductive planning.93,94 Phenylketonuria,
which is included in the panels of most of the providers, is a treatable
condition, although treatment (diet) may be challenging. It is
associated with good prognosis as it is already diagnosed early in
newborn screening programmes. For some treatable disorders, know-
ing that both parents are carriers could improve the prognosis if the
diagnosis thereby can be made earlier, but this must be explained in
the pre-test information. It is not unthinkable, though, that couples
planning a pregnancy will consider requesting prenatal diagnosis or
pre-implantation genetic diagnosis for these disorders. The lists of
disorders included in the expanded carrier testing panels differ among
test providers. There are differences in numbers and types of diseases,
in the ages of onset (neonatal, childhood, adult life) and in treatability
and severity.86
As previously mentioned, there are currently 1300 known recessive
(autosomal and X-linked) diseases and about 100 of these have a
prevalence of 41/100 000.88 Several important conditions, for exam-
ple, Duchenne/Becker muscular dystrophy and Friedreich ataxia are
not included in any of the commercial panels, presumably due to
technological limitations of the microarray-based testing approach (eg,
trinucleotide repeat mutations). We propose that, pending convincing
evidence to the contrary, retaining a ‘serious congenital and childhood
onset disorders’ scope is important in panel design. This is in line with
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the scope that was also proposed in a recent joint ESHG/ASHG
document on non-invasive prenatal testing.95 As expressed in that
document ‘This can be justiﬁed in the light of the normative
framework as providing women or couples with meaningful repro-
ductive choices rather than with the (theoretical) option of receiving
all information that genomic technologies can possibly reveal about
the fetus.’ There is no general agreement on classiﬁcation of genetic
disorders based on the severity of disease.96 Nevertheless, a systematic
classiﬁcation of disease severity in the context of expanded carrier
screening has been recently proposed in a study described by Lazarin
et al.97 based on health care professionals’ opinion. Disease character-
istics that scored highest in their study included shortened life span,
intellectual disability, impaired mobility and internal physical
malformation.
For some conditions carrier screening could also reveal increased
risk of morbidity for potential carriers. For example, heterozygous
carriers for sequence variants in the glucocerebrosidase gene (included
in several screening panels and related to autosomal recessive Gaucher
disease) have a signiﬁcantly increased risk of developing Parkinson’s
disease in later life.98 Carriers of Ataxia Telangiectasia have an
increased lifetime risk for breast cancer; and carriers of the Fragile X
(FMR1) premutation have an increased risk of primary ovarian
insufﬁciency and can develop a neurodegenerative disorder (Fragile
X-associated Tremor/Ataxia Syndrome; FXTAS) in adulthood.99 In the
future, more associations between carrier states and increased or
decreased risks for diseases will likely be revealed, and these will
increase the complexity of counselling for expanded carrier screening.
In addition to the impact for the individual or couple, identiﬁcation
of some sequence variants may have implications for the extended
family members, leading to speciﬁc carrier testing and reproductive
options. Therefore, potential clinical consequences in heterozygous
carriers should be adequately covered in the provision of pre- and
post-test information.
Ethical, legal and (psycho)social issues
The responsible introduction of expanded carrier screening requires a
careful appraisal of the advantages and disadvantages for the target
population. Among the advantages are the reproductive options that
the offer of carrier screening might lead to. Nevertheless, it is also
important to discuss some of the ethical, legal and (psycho)social
concerns that might be connected to a carrier screening offer.
Issues of autonomy and informed consent
The introduction of genetic reproductive screening programmes in the
general population raises many concerns about complex decisions
such as prenatal diagnosis and selective termination of pregnancy.
Although guidelines have emphasised the need for genetic screening to
be voluntary, non-coerced and based on an informed choice, these
concerns recognise the difﬁculties in implementing such guidance.
Ensuring that individuals are aware of the purpose of the screening
and the possible implications of the results (including understanding
of the residual risk in a screen-negative result) will be increasingly
difﬁcult if more conditions with differential implications are included
in a screening panel.13,14 Since the stated aim of reproductive
screening (including carrier screening) here is not prevention, but
rather the provision of options for reproductive decision making,
appropriate pre-test information and voluntary decision making
becomes an essential requirement rather than a mere side-constraint:
without this, the screening cannot fulﬁl its aim.
Gaining valid consent has been considered much more challenging
the more carrier screening panels expand. As a result of ‘information
overload’, this may paradoxically undermine rather than serve the very
aim of providing options for meaningful reproductive choice.100
Suggested ways around this include the development of uniform
and coherent panels. Elias and Annas101 proposed the concept of
generic consent as a way to safeguard informed decision making
in situations where information overload is threatening. In this
approach, prospective testees would be generally informed about types
of possible test outcomes and implications.102 They would be told that
the procedure is carried out to identify individuals/couples, for
example, at an elevated risk of having a child with a severe disability.
Some of these diseases, as well as associated clinical symptoms, can be
brieﬂy mentioned as illustrative examples. The limitations of the test,
such as the possibility of false positive and false negative results, should
be included in such generic consent. For those couples identiﬁed as
carriers, more detailed follow-up counselling would be important.101
Recently, the ACMG acknowledged the advantages of generic consent
in the context of expanded carrier screening. In a policy paper
published in June 2013 it is stated that: ‘A highly multiplex approach
will require a more generic consent process than is typically used for
single-disease screening because it may not be practical for a clinician
to discuss each disease included in multi-disease carrier screening
panels’.17 Such consent comes with some concerns: less detailed
information could lead to less informed decisions,103 and the type of
information may need to be adapted for speciﬁc groups. In contrast,
some individuals might require more speciﬁc and in-depth informa-
tion to make a decision regarding screening.101 In order to meet the
needs of individuals seeking in-depth understanding of the carrier
screening procedure, usage of appropriately tailored information
pamphlets, websites and other audio-visual aids might be useful.
Tailoring of modern technologies, for example, smart-phone apps,
could help to ensure that all interested patients can make informed
choices about carrier screening programmes.
Individual and community impact
Learning about carrier status by participating in a carrier screening
programme could impact on: (1) psychological well-being, (2)
perceptions of health and (3) (feelings of) discrimination or stigma-
tisation (social consequences).
Impact on psychological well-being. Studies have demonstrated
increased distress levels among carriers, but most are not clinically
signiﬁcant and/or levels return to normal shortly after.104–106 When
screening is offered to couples, taking a sample from both partners at
the same time prevents the anxiety and the need for counselling that
might arise among those who are tested positive while the other
partner is asked to provide a sample to be tested.107 Sampling one
partner later can also be harder to organise. As more disorders are
added to screening panels, the chance of being a carrier of
something, or being a carrier couple, increases. Couple-based
disclosure – where a result is only positive if both members carry
the same condition – would reduce anxiety in a + /− couple (ie,
one partner tests positive while the other tests negative), since they
would receive an overall negative result.108 However, this means
that individual carriers are not notiﬁed, so that a test would have to
be repeated with a new partner, and informing relatives would
happen in fewer cases.
In a study evaluating a carrier screening programme in high schools
for the AJ population in Australia, it was shown that expanding the
screening from one disease (TSD) to six increased the number of
students who anticipated negative feelings if found to be a carrier of
one of the conditions.19 Considering that in an expanded carrier
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screening programme many (rare) autosomal recessive disorders but
also X-linked disorders will be included, the potential psychological
impact could increase, as this will also allow to identify carriers of
multiple recessive conditions. The possibility of psychological harms
could be minimised by educating prospective test-takers about the
screening programme, and about the implications of being a carrier.
For example, a (still ongoing) Australian study screening for Fragile X
syndrome carriers showed minimal impact, possibly also due to
intensive counselling and women given the opportunity to deliberate
their decision to screen.109 In contrast, carrier screening for beta-
thalassaemia in Australia occurs with every pregnant woman in a very
ad hoc fashion (ie, through initial full blood examination) with little (if
any) pre-test counselling and also minimal education even post test.110
Consequently, thalassaemia carriers often misunderstand their
status.111 As testing becomes more common people will become
aware that all individuals are carriers for a limited number of sequence
variants and this may decrease anxiety. Efforts should be undertaken
to promote programmes that enhance genetic knowledge of the
public.
Impact on perceptions of health. Some earlier studies have described
less optimistic health perceptions after receiving positive test
results,104,112,113 although others have found no impact of screening
on health perceptions.114,115 In a 3-year follow-up study on prenatal
carrier screening for CF there was a small negative effect on how
carriers perceived their current health.104 Similarly, in a preconception
CF carrier screening programme it was found that carriers perceived
themselves as less healthy.113 Several explanations, such as reduced
optimism of carriers about their health and poor understanding
of the test results, have been suggested for this ﬁnding.112
Expanding screening to more diseases may increase the miscon-
ceptions about health status of carriers and induce more anxiety.19
This may be complicated by the overall limited public (and
professional) knowledge of genetics and lack of awareness of
genetic diseases.
Stigmatisation and discrimination. Stigmatisation is the effect of
labelling a group or person with negative social or psychological
characteristics. Stigmatisation of carriers within the community is one
concern that has been described, for example, with regard to the
orthodox Jewish premarital screening programme Dor Yeshorim.9,116
Moreover, some genetic diseases are more prevalent in certain groups
based on ancestry. Therefore, members of a particular group or
subpopulation may be or feel stigmatised or discriminated against as a
result of carrier status information. Encouragingly recent studies have
revealed no predominant feelings of discrimination or social stigma
among carriers, but in the 1970s, screening programmes for sickle cell
disease resulted in misunderstanding of carrier status; fear and
widespread discrimination and stigmatisation of African-American
carriers, and insurance companies refused health and life insurance to
sickle cell carriers as a result of their own misinformation.117 Similar
ﬁndings have been reported from other earlier screening
programmes.118 One way to minimise these issues is to improve
community education and public campaigns and appropriate infor-
mation and counselling. Moreover, it has been suggested that
addressing the whole population for screening but using a decisional
aid to determine the risk of disease, and thus eligibility for testing as a
selection from particular disorders, based on ancestral background
might avoid stigma,119 especially if almost any couple would be eligible
for some form of testing. Increased intermarriage, however, compli-
cates delineation of who is at risk. Expanded carrier screening might,
in fact, decrease stigmatisation as screening could be offered as a
‘universal test’ rather than targeted to a particular subpopulation.
Concerns have been raised that carrier detection devalues the lives
of affected patients or impedes the search for a cure because they are
seen to be associated with encouraging a reduced birth prevalence of
affected children. Other concerns about carrier screening include
conﬁdentiality of test results and fear of undue pressure on individual
choice15 in particular in socially tight communities9 or schools. ‘Peer
pressure’ has been reported as a reason to participate in high-school
carrier screening,49 although a study offering hereditary haemochro-
matosis in the high-school setting showed that o1% of the students
indicated that the decisions of their friends/peers inﬂuenced their
participation in screening.120
Equity and fairness. Although the introduction of expanded screen-
ing universally offered to the whole population regardless of ancestry
can be regarded as increasing equity (access for everyone), a justice
concern is that those who might proﬁt most may be less well helped
by that offer. First, a universal offer may undermine the awareness of
risk among those in higher risk groups. Second, because universal
screening panels may cover a lower number of sequence variants than
would be considered appropriate in an ancestry-based screening offer,
there would still be a need to target those groups separately, which
raises logistical complexities. When considering universal carrier
screening, providers and health authorities should be aware of these
possible drawbacks and make sure that services are in place to avoid
unfair treatment of those at the highest risk.
False reassurance. For people who are found to not carry a disease
allele after screening, it is important that the different aspects of
screening are well understood. A negative (favourable) carrier test
result, received by the majority of those screened, may result in relief
among participants. Previous studies have demonstrated that this may,
however, also result in a false sense of security (false reassurance), as a
considerable number of people who receive a screen-negative result
mistakenly believe that they are deﬁnitely not carriers.19,104,113 As most
carrier screening tests still convey a small residual risk – mostly due to
incomplete sensitivity of the test – after a favourable test result (if one
partner or even both partners are negatively tested) these couples may
thus be confronted with the unexpected birth of a child with the
disease. Furthermore, many pregnancy risks other than recessive
diseases have not been included. Health care professionals thus need
to address potential misperceptions that expanded carrier screening
can guarantee a healthy child.
Conversely, couples may take far-reaching reproductive decisions
(eg, refraining form having children) that might not have been needed,
either because of a lack of understanding of test-results or because
panels are unsufﬁciently validated.
Commercial offers
The development of expanded carrier screening has until now been
largely stimulated by commercial offers, often directly to consumers.
On the one hand broader access to genetic testing services directly to
the consumer might enhance their reproductive autonomy, on the
other it might also raise concerns due to the absence or uncertain
quality of pre- and post-test information, counselling and/or medical
supervision.92 Moreover, as noted earlier, various concerns exist about
the conditions included in various panels (eg, mild diseases) as well as
the inclusion of variants of unknown signiﬁcance or variants that are
not clearly pathogenic. Finally, commercial offers might lead to an
increased burden on public health resources due to an increased call
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on primary care physicians, clinical genetic services or other health
care professionals for more information or counselling.
Summary points (III)
 Currently the commercial offer of expanded carrier testing is of limited clinical
validity in terms of reproductive carrier screening, especially where it includes
diseases that are not considered severe or have onset in adulthood (in which case
they should not be offered for the purpose of facilitating reproductive decisions).
 Carrier screening may reveal clinically relevant disease risk for a screened
individual.
 Expanded carrier screening will lead to the detection of more carriers and carrier
couples. Generally there is no lasting negative effect of carrier status on anxiety,
self-concept or stigma, although false reassurance for some needs to be taken into
account.
 Gaining valid consent is much more challenging, as well as time-consuming, the
more carrier screening panels expand and may require new models of consent (eg,
generic consent).
CONCLUSION AND RECOMMENDATIONS
Obviously, carrier screening for single-gene disorders is not new;
however, the screening naturally expands as the range of disorders
included in the screening expands; the pick up of ‘carrier couples’ is
much greater as more conditions, genes and sequence variants can be
screened for simultaneously than hitherto possible. By summarising
the knowledge gained from several decades of population-based carrier
screening, the aim of this document is to contribute to the public and
professional discussion on expanded carrier screening, in order to
provide recommendations for health care professionals, laboratory
experts and health authorities. In discussing responsible implementa-
tion of carrier screening, an adequate and proportional balance of
advantages and disadvantages should be achieved. Carrier screening is
deﬁned here as the detection of carrier status in couples or individuals
who do not have an a priori increased risk for having a child with a
certain disease based on their own or their partner’s personal and/or
family medical history. The introduction of new technologies, such as
NGS, provides opportunities for expanded carrier screening panels for
multiple autosomal and X-linked recessive disorders. Expanded carrier
screening allows testing of all individuals regardless of ancestry or
geographic origin. In order to minimise potential adverse psychosocial
impact of carrier tests and ensure quality of tests, it is advised that such
tests should comply with quality control and information standards,
irrespective of whether they are offered through the national health
care systems or through commercial companies.121 Research into the
ﬁnancial aspects of introducing expanded carrier screening into public
health systems is needed. New funding models facilitating a partici-
patory model (private payment of tests) and access to high-quality
public sector facilities should also be explored.
On the basis of the evidence reviewed in this paper, the following
recommendations are made:
1. Primary purpose of carrier screening: The primary objective of
carrier screening in individuals or couples without a known family
risk of recessive disorders should be to inform them of possible
genetic disease risks in future offspring and of the reproductive
options available in order to enable autonomous choices.
2. Expanded carrier screening: In line with the primary purpose,
priority should be given to carrier screening panels that include
(a comprehensive set of) severe childhood-onset disorders. Tests
should be designed to achieve high clinical validity (clinical
sensitivity, negative and positive predictive values) and should
have established clinical utility. The main focus should be on
reporting sequence variants that clearly affect function (with clear
clinical signiﬁcance).
3. Evidence: Before initiating expanded carrier screening it is
necessary to establish an acceptable evidence base that should be
continuously developed and solidiﬁed while screening takes place.
This includes evidence about the signiﬁcance of the screened
sequence variants, the sensitivity and speciﬁcity of the tests, the
immediate and downstream costs related to the test and screening
offer, the psychological and social impact of a carrier screening
offer, the types of interventions that could improve informed
decision making as well as the public acceptability of carrier
screening. More information on rare cases where carriers are
affected to some degree is needed.
4. Timing of carrier screening: Expanded carrier screening should
ideally be offered preconceptionally as this maximises reproduc-
tive options (and thus increases reproductive autonomy) and has
fewer time constraints, resulting in less emotional distress than
when a test is performed during pregnancy.
5. Reproductive decision making: As the primary objective is to
strengthen reproductive choices and decision making of couples,
the effectiveness of carrier screening programmes should be
measured by assessing the extent to which it optimises informed
choice and reproductive decision making and not by demonstrat-
ing how much it reduces the birth prevalence of affected children.
This requires good follow-up information of those taking part.
6. Information and support: Expanded carrier screening will lead to
the detection of more carrier couples (as well as more couples in
which one partner tests positive while the other tests negative).
Attention should therefore be given to psychological, social and
counselling-related aspects, including explaining the reproductive
options, potential consequences for relatives and the limitations of
carrier screening such as the residual risk in a screen-negative
result or interpretation of the functional impact of sequence
variants. Psychosocial support and pre-and post-test information
should be available (with test results provided in a timely and
sensitive manner). Post-test clinical genetic counselling should be
available and offered by genetic professionals to all carrier couples.
Individual pre-test genetic counselling should be made available
for those who request it. Given that this offer is to be provided to
individuals (or couples) with an initial low risk and limited
awareness of the disorders screened for, it is important to inform
the public properly about these disorders and the various aspects
of carrier screening. This may be achieved using different methods
including media, leaﬂets and programmes in schools.
7. Informed consent: In the context of screening for multiple genetic
disorders, the challenge is to adequately inform couples at the pre-
test stage about the goal, concept and implications of carrier
screening, without having to explain every disorder to be screened
for individually, as that would be impossible with expanding
panels. Although new models of consent (eg, ‘generic consent’)
have been proposed to meet this challenge, their introduction in
this context requires evaluation, in order to explore whether this
leads to couples making well-informed decisions about whether or
not to accept the screening offer. Potential clinical consequences
in heterozygous carriers should be adequately covered in the
provision of genetic information and in the informed consent
before testing.
Responsible implementation of expanded carrier screening
L Henneman et al
e9
European Journal of Human Genetics
8. Voluntary participation: Decisions to have expanded carrier
screening should be voluntary and informed: Individuals or
couples should be sufﬁciently informed of the beneﬁts, disadvan-
tages and limitations of the screening test, and consent should be
freely given with sufﬁcient time to decide; there should be equity
of access to testing services.
9. Quality of services: Genetic testing, as well as the provision of
genetic information and counselling, should be provided by
accredited genetic services and appropriately trained professionals.
10. Maximising quality of care: It should be made explicit to those
receiving expanded carrier screening that care will continue to be
provided to them regardless of their reproductive choices. In some
cases, carrier screening could also contribute to the identiﬁcation
of disorders that might lead to early therapeutic procedures in
affected offspring. This information should be adequately pre-
sented to couples. The availability of carrier screening should not
be used as a rationale for reducing the quality of care available for
children born with disease: standards of care should be
safeguarded.
11. Professionals and public education and dialogue: Health care
professionals involved in the provision of expanded carrier
screening should receive appropriate education and training.
Public understanding of genetics and carrier screening, including
the beneﬁts and limitations needs to be strengthened, recognising
that the perception of the harms and beneﬁts of screening is very
different among different stakeholders. For this reason, it is
important to have an open dialogue about the expected beneﬁts
and harms with all stakeholders, including patients and their
representatives and the general public. This would enable key
frameworks to be developed, in order to support informed
decision making.
12. Governance: Governments and public health authorities should
adopt an active role in discussing the responsible introduction of
expanded carrier screening. This entails developing an implemen-
tation plan, ensuring quality control also extending to the non-
laboratory aspects such as providing information and counselling,
education of professionals, systematic evaluation of all aspects of
the offer as well as promoting equity of access, and setting up a
governance structure for responsible further innovation. Govern-
ments and public health authorities should also develop oversight
on the quality of genetic testing services provided by commercial
companies.
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